Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Roll-over ceritinib treatment in ALK-positive malignancies
2024-511040-58-00Phase 4Authorised
- Sponsor
- Novartis
- Start
- Jan 2016
- Modality
- Small Molecules
- Countries
- 20
01
Overview
Phase 4, open-label, single-arm trial of ceritinib in non-small cell lung cancer (NSCLC) and Anaplastic Large Cell Lymphoma ALK-positive, sponsored by Novartis. Primary endpoint: Frequency and severity of AEs/SAEs. Planned start Jan 2016; status: authorised.
02
Drugs
ceritinib
03
Conditions
non-small cell lung cancer (NSCLC)Anaplastic Large Cell Lymphoma ALK-positive
Beyond the preview
Go deeper on 2024-511040-58-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511040-58-00.